10-K: OnKure Therapeutics (OKUR) Files 10-K Annual Report for Fiscal Year 2024

OnKure Therapeutics reports its 2024 financial results and provides an update on its clinical development programs, including OKI-219.

Summary

• OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, has filed its 10-K annual report for the fiscal year ended December 31, 2024.
• The company is focused on developing precision medicines targeting biologically validated drivers of cancers.
• Their lead product candidate, OKI-219, is a highly selective inhibitor of PI3K H1047R, currently in a Phase 1 clinical trial.
• In December 2024, OnKure announced preliminary safety, tolerability, and pharmacokinetic data from the PIKture-01 trial, showing OKI-219 was well-tolerated.
• The company expects to report additional single-agent data and initial combination data with fulvestrant in the second half of 2025.
• OnKure is also pursuing pan-mutant and helical domain PI3K inhibitor development candidates, with announcements expected in the second quarter of 2025 and 2026, respectively.
• The company's net losses were $52.7 million for 2024 and $35.3 million for 2023.
• As of December 31, 2024, OnKure had cash and cash equivalents of $110.8 million, expected to fund operations into the fourth quarter of 2026.
• The company will need to raise substantial additional capital to fund its general corporate activities and to fund its research and development.
• On October 4, 2024, Reneo Pharmaceuticals, Inc. completed its merger with OnKure, Inc., changing its name to OnKure Therapeutics, Inc.
• The company is subject to extensive regulations by the FDA and other federal and state authorities.
• As of March 7, 2025, OnKure had 46 employees, 35 of whom were engaged in research and development activities.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the potential of OnKure's pipeline and the challenges it faces, including financial losses and the need for additional funding. The positive clinical data is tempered by the risks inherent in drug development and regulatory approval.

Positives

• OKI-219 was well tolerated across all dose levels with no hyperglycemia, stomatitis, or rash observed with other PI3K inhibitors.
• OKI-219 dosed at 900 mg twice daily showed steady-state exposure levels with near-continuous coverage of the in vivo EC 80 for pAKT inhibition.
• Preclinical data for OKI-219 in a rat model suggest that OKI-219 is highly brain-penetrant, reaching free drug concentrations in the brain similar to those observed in plasma, indicating potential utility in central nervous system disease.

Negatives

• OnKure has incurred significant net losses since inception and expects to continue to incur significant net losses for the foreseeable future.
• The company has never generated revenue from product sales and may never achieve or maintain profitability.
• OnKure will need substantial additional funding before it can complete the development of its product candidates.
• The market price of OnKure's Class A Common Stock has been and is expected to continue to be volatile.

Risks

• OnKure is substantially dependent on OKI-219, and its failure to advance OKI-219 through clinical development would materially harm the business.
• Clinical trials of OnKure's product candidates may fail to demonstrate safety and efficacy.
• The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable.
• OnKure faces substantial competition which may result in others discovering, developing or commercializing products before or more successfully than OnKure does.
• OnKure may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws and health information privacy and security laws, which could expose OnKure to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.

Future Outlook

OnKure expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through clinical trials and pursues additional discovery programs. The company believes its current cash resources are sufficient to fund planned operations into the fourth quarter of 2026 but will require additional capital to fully execute its development plans.

Industry Context

The report highlights the competitive landscape of the pharmaceutical and biotechnology industries, particularly in the development of PI3K-targeted therapies. It notes the presence of both marketed medicines and novel therapies in clinical development, emphasizing the need for highly selective inhibitors to improve efficacy and safety.

Comparison to Industry Standards

• The document compares OnKure's approach to PI3K inhibition with existing therapies like alpelisib (Piqray), capivasertib (Truqap), and inavolisib (Itovebi), noting their limitations in selectivity and associated toxicities.
• It mentions competing PI3K-targeted therapies in clinical development, including gedatolisib (Celcuity Inc.), MEN1611 (Menarini), TOS-358 (Totus Medicines), RLY-2608 (Relay Therapeutics), STX-473 (Scorpion Therapeutics) and SNV4818 (Synnovation Therapeutics).
• The document highlights the potential market opportunity for PI3K inhibitors, estimating the number of HR+/HER2advanced breast cancer patients with common PI3K mutations in the U.S. and other regions.

Corporate Governance

Legal Proceedings

• Two complaints were filed in the Supreme Court of the State of New York, County of New York, alleging misrepresentations and omissions in the Proxy Statement/Prospectus relating to the Merger.
• The Complaints assert violations of negligent misrepresentation and concealment in violation of New York common law and negligence in violation of New York common law.
• The Complaints sought orders enjoining the proposed Merger, or in the event that the Merger was consummated, orders rescinding the Merger or awarding actual and punitive damages, as well as all of the plaintiffs fees and expenses in connection with the litigation, including reasonable attorneys and experts fees and expenses.

Related Party Transactions

• On January 10, 2025, we entered into a sublease agreement with Ambros Therapeutics, Inc. (Ambros Therapeutics), pursuant to which we subleased certain office space to Ambros Therapeutics for their corporate headquarters. Mr. Flesher, the President and Chief Executive Officer of Reneo prior to the Merger, is acting President and the Chief Executive Officer and a stockholder of Ambros Therapeutics. The premises are located in Irvine, California. The approximate value of the transaction is $450,000 over the term of the Sublease. The Sublease was considered by us in accordance with our Related Person Transactions Policy, and approved by Audit Committee.

Stakeholder Impact

• Shareholders: The report provides information relevant to investment decisions, including financial performance, clinical development progress, and potential risks.
• Employees: The report discusses employee compensation, benefits, and the company's commitment to attracting and retaining talent.
• Patients: The report highlights the company's focus on developing precision medicines to improve clinical outcomes for cancer patients.
• Creditors: The report provides information about the company's financial condition and ability to meet its obligations.

Next Steps

• Continue clinical development of OKI-219 in various combinations and lines of treatment for breast cancer.
• Announce a pan-mutant PI3K development candidate in the second quarter of 2025.
• Announce a helical domain PI3K inhibitor development candidate in 2026.
• Seek regulatory approval for current and future product candidates in the United States and abroad.
• Evaluate strategic opportunities to maximize the commercial potential of product candidates.

Key Dates